Building on the demand for remote technology applications during the Covid-19 pandemic, digital health is enabling a realignment of health provision around integrative disease management combined with personalized wellness solutions – goals that will hopefully secure better outcomes for patients.

With rising levels of real-time and actionable data, backers of digital health also promise lower costs per episode of care as well as helping regulation and clinical management protocols become more targeted and efficient.

Of course, none of these transformative gains would be possible without this community of digital innovators, whose impact is registered by the 25 software apps and platforms, devices and diagnostics the Galien USA Awards Committee has nominated for 2023’s “best in class” – double the number from last year.

To mark the Prix Galien USA’s upcoming October 23-27 “Galien Week of Innovation”, members as well as guest experts of the Prix Galien Awards USA Committee will chair five webinars highlighting each of the 24 nominated products in the Best Pharmaceutical Product category.

These virtual panel exchanges will offer the opportunity for webinar participants to assess the current state of innovation in branded pharmaceuticals, covering key aspects of clinical progress and therapeutic differentiation; new access challenges, especially in a changing US market characterized, for the first time, by public price negotiations; and upcoming
developments in next-generation platform technologies, medicines and vaccines.

Top of mind will be the transformative – and possibly disruptive – effects of this new science on health system productivity and patient outcomes worldwide.

To mark the Prix Galien USA’s upcoming October 23-27 “Galien Week of Innovation”, members of the Prix Galien USA Awards Committee and invited experts will chair a webinar highlighting the four nominated products in the Best Product for Rare/Orphan Diseases category.

This virtual exchange will offer the opportunity for webinar participants to assess the current state of innovation in branded rare and orphan disease products, covering key aspects of clinical progress and therapeutic differentiation; new access challenges, especially involving novel pricing for medicines with high price tags for small populations; and the latest developments in next-generation technology platforms and personalized treatments based on extensive mapping of individual DNA and cell structures.

Top of mind will be the transformative – and possibly disruptive – effects of this new science on health system productivity and patient outcomes worldwide.

To mark the Prix Galien USA’s upcoming October 23-27 “Galien Week of Innovation” members of the Prix Galien USA Awards Committee and invited experts will chair three webinars highlighting each of the 28 nominated products in the Best Medical Technology category.

These virtual panel exchanges will offer the opportunity for webinar participants to assess the current state of innovation in branded medical technology devices and diagnostics, covering key aspects of clinical progress and therapeutic differentiation as well as new access challenges as the US institutional health infrastructure confronts significant budgetary constraints.

Top of mind will be the transformative - and possibly disruptive - effects of new technologies like AI on health system productivity and patient outcomes worldwide.